DataMeds AI Soars on $1.5 Million Helomics Acquisition

DataMeds AI MEDS shares experienced a significant surge on Wednesday morning after completing its acquisition of Helomics, an AI cancer diagnostics laboratory and precision oncology contract research organization.

The deal equips DataMeds AI with a fully operational CLIA/CAP-certified clinical laboratory, specialized CRO research services, and $1.5 million in cash, valuing the transaction at $1.5 million.

Despite the 5x rally on Wednesday, DataMeds AI stock is still down around 60% since the start of this year (2026), with a market capitalization under $6 million and approximately 3.1 million outstanding shares following a 1-for-50 reverse stock split earlier in 2026.

The acquisition provides an operational foundation for DataMeds AI, but investors must evaluate the micro-market mechanics driving this volatility, as the massive pop is largely propelled by low-float volume expansion and retail momentum chasing.